Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Merck
AstraZeneca
Express Scripts
McKesson

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 5,989,873

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 5,989,873
Title: Method of detecting gene expression and/or of preventing such expression in cells
Abstract:A method of amplifying a nucleotide sequence complementary to an mRNA template derived from genomic DNA. The method involves the following steps. A sample mixture containing an mRNA template and corresponding genomic DNA is provided, the genomic DNA including at least two exons separated by at least one intron. A pair of intron-blockers are introduced into the mixture, the intron-blockers comprising a sequence of intron-specific oligonucleotides modified to prevent nucleotide extension in conditions promoting polymerase chain reaction. A primer pair promoting amplification of cDNA derived from the mRNA template is introduced into the mixture and then reverse transcription polymerase chain reaction is carried out to amplify cDNA. Detection of the cDNA is proof of the existence of mRNA in the sample, and thus proof of expression of the corresponding gene. The method avoids false positives caused by amplification of genomic DNA as well as cDNA based on an mRNA template. The invention includes a method of suppressing gene expression in vivo, which comprises exposing cells containing a gene to be suppressed, made up of exons and at least one intron, to intron-blockers having nucleotide sequences that bind to the intron to prevent gene expression.
Inventor(s): Vinayagamoorthy; Thuraiayah (Saskatoon, Saskatchewan, CA), Schloss; Eric (Edmonton, Alberta, CA)
Assignee:
Application Number:08/929,302
Patent Claims:1. A method of amplifying a nucleotide sequence complementary to an mRNA template derived from genomic DNA, which comprises:

providing a sample mixture containing an mRNA template and corresponding genomic DNA, said genomic DNA including at least two exons separated by at least one intron,

introducing intron-blockers into said mixture, said intron-blockers comprising a sequence of intron-specific deoxyribonucleotides modified to prevent nucleotide extension in conditions promoting polymerase chain reaction, and

carrying out reverse transcription polymerase chain reaction on said mRNA template, to amplify said cDNA, in the presence of a polymerase and a primer pair promoting amplification of cDNA derived from said mRNA template.

2. A method according to claim 1 wherein said polymerase does not have 3'-5' exonuclease activity, and wherein said intron-specific deoxyribonucleotides have been modified to prevent chain extension by a method selected from the group consisting of:

a) replacement of an --OH group at a 3.sup.rd position of a last nucleotide at the 3'-end of the deoxyribo oligonucleotide, resulting in non-availability of the hydroxyl group for phosphodiester fromation;

b) removal or molecular change of a purine or pyrimidine base molecule of a last nucleotide at the 3'-end of the deoxyribo oligonucleotide, resulting in a lack of annealing of the nucleotide at this end; and

c) providing a non-phosphodiester bond between a penultimate and a final nucleotide at the 3'-end of the deoxyribooligonucleotide, creating stoichiometric constraints for purine or pyrimidine base pairing.

3. A method according to claim 1 wherein said polymerase has 3'-5' exonuclease activity, and wherein said intron-specific deoxyribooligonucleotides have been modified to prevent chain extension by a method selected from the group consisting of:

a) replacement of an --OH group at a 3.sup.rd position of a last nucleotide at the 3'-end of the deoxyribo oligonucleotide, resulting non-availability of the hydroxyl group for phosphodiester formation; and

b) removal or molecular change of a purine or pyrimidine base molecule of a last nucleotide at the 3'-end of the deoxytribooligonucleotide, and formation of a non-phosphodiester bond between a penultimate and a final nucleotide a the 3'-end of the deoxyribo oligonucleotide, preventing 3'-5' exonuclease activity.

4. A method of detecting a specific mRNA derived from genomic DNA, which comprises:

providing a sample mixture potentially containing an mRNA template and corresponding genomic DNA, said genomic DNA including at least two exons separated by at least one intron,

introducing intron-blockers into said mixture, said intron-blockers comprising a sequence of intron-specific deoxyribooligonucleotides modified to prevent nucleotide extension in conditions promoting polymerase chain reaction,

carrying out reverse transcription polymerase chain reaction to amplify said cDNA in the presence of a polymerase and a primer pair promoting amplification of cDNA derived from said mRNA, and

detecting amplified cDNA as a confirmation of mRNA in said sample mixture.

5. A method according to claim 4 employing deoxyribooligonucleotides incorporating detectable labels as said primers and detecting said amplified DNA by detecting said labels.

6. A method of distinguishing fetal cells from maternal cells in a sample taken from a pregnant female, comprising:

providing a sample potentially containing fetal cells or maternal cells;

preparing said sample for reverse transcriptase polymerase chain reaction;

introducing intron-blockers into said prepared sample, said intron-blockers comprising oligonucleotides modified to prevent nucleotide extension in conditions promoting polymerase chain reaction, and having sequences complementary to intron regions of an alpha feto protein gene;

carrying out reverse transcription polymerase chain reaction on said mRNA template in the presence of a primer pair promoting amplification of cDNA derived from said mRNA template transcribed from said alpha feto protein gene; and

detecting amplified cDNA as a confirmation of a presence of said alpha feto protein gene as confirmation that said cells are fetal cells and hence distinguish the fetal cells from maternal cells.

7. A method of detecting viral infection in tissue transplants, which comprises detecting expression of mRNA characteristic of viral DNA in a sample of transplant tissue, by:

treating said sample to prepare said sample for reverse transcriptase polymerase chain reaction,

introducing intron-blockers into said treated sample, said intron-blockers comprising a sequence of intron-specific deoxyribooligonucleotides modified to prevent nucleotide extension in conditions promoting polymerase chain reaction, said deoxyribo oligonucleotides annealing to intron regions within said cellular genomic DNA, and

carrying out reverse transcription polymerase chain reaction, in the presence of a polymerase and a primer pair promoting amplification of cDNA derived from said viral mRNA.

Details for Patent 5,989,873

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Sign up for a Free Trial 2016-09-24
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Sign up for a Free Trial 2016-09-24
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Mallinckrodt
Medtronic
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.